Maravai LifeSciences' (MRVI) TriLink BioTechnologies said Monday it partnered with Avantor (AVTR) to expand the availability of its innovative nucleic acid products to customers across Europe, the Middle East, and Africa.
The company said the distribution partnership is expected to streamline the ordering process and shorten lead times for European customers.
Under the agreement, TriLink's key products, including CleanCap cap analogs, catalog mRNAs, over 150 modified and unmodified nucleotides, and high-performance IVT enzymes like CleanScribe RNA Polymerase, are more widely available in the region.
It added that TriLink's products will soon be available on Avantor's eCommerce platform, MarketSource.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.